| |  Scientists have developed a strategy to boost the cancer-fighting power of natural killer (NK) cells, part of the immune system's first line of defense. | |
|
| |  As the body ages, cells naturally accumulate dozens of genetic mutations each year. New research from Boston Children's Hospital, published in Cell, finds that the brain's resident immune cells, microglia, amass mutations in specific cancer-driving genes yet they don't manifest as cancer. | |
|
| |  Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) exhibit significant metabolic dysregulation, which impairs their antitumor function. | |
|
| | Scientists have long been puzzled by how maturing red blood cells manage to produce all the hemoglobin they need to carry oxygen to tissues, even after shedding the vital structures they need to produce it. | |
|
| | Older adults recovering from serious blood clots often face long periods of hospitalization or rehabilitation due to a higher rate of recurrence. | |
|
| |  For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an "identity crisis." | |
|
| |  A cancer diagnosis can upend any life. For young adults already navigating a step into independence, it can be especially distressing. | |
|
| |  It may be possible to identify which pre-cancerous cells will develop into a rare type of blood cancer, due to new research showing that a single genetic change drives myeloid leukemia in children with Down syndrome. | |
|
| |  Although patients with the same cancer diagnosis may respond very differently to treatment, clinicians still have limited tools at their disposal to predict who is most likely to benefit or suffer from a particular myeloma therapy. | |
|
| | A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22. | |
|
| | Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15. | |
|
| | Early exposure to PFAS, a group of widely used compounds known as "forever chemicals," was associated with a higher risk of acute lymphoblastic leukemia, the most common childhood cancer, according to University of California, Irvine Joe C. Wen School of Population & Public Health researchers. | |
|
| | As we age, our ability to maintain healthy blood and a strong immune system gradually declines, largely because hematopoietic stem cells (HSCs), the cells responsible for producing all blood cell types, begin to lose their effectiveness. | |
|
| |  Despite reducing amyloid plaques, antibody treatments for Alzheimer's fail to improve cognition, highlighting critical gaps in current therapeutic approaches. | |
|
| |  Circulating white blood cells called neutrophils are some of the immune system's first responders. Their numbers shoot up during infection and inflammation, shifting the ratio of neutrophils to other types of immune cells in the blood. | |
